A small side benefit of having 30% in immunotherapies, while it is being funded with $18m, is that as our third pillar, it keeps AHZ a little more complex.
Clearly AHZ has the potential to be $10 in 5 years. However, biotech / medtech is an industry sector rife with takeovers. The more complex (and higher market cap / PE ratio) the less palatable we are for an opportunistic $1 or $2 takeover.
